Eli Lilly's lead in the obesity race has increased. Its recent stock performance says otherwise.
Eli Lilly investors have received some very good news in recent months, with one notable exception regarding the stock's performance.…
Eli Lilly investors have received some very good news in recent months, with one notable exception regarding the stock's performance.…
Life sciences company Danaher certainly hasn't been an easy stock to buy this year. A wave of new companies going…
Eli Lilly has outperformed the S&P 500 for five straight years as Wall Street realized its huge opportunity in obesity…
The new trial data has cemented Club's lead position behind Eli Lilly in the highly competitive anti-obesity drug race. Eli…
Enthusiasm for Eli Lilly, the club's holding company, needs to be tempered, at least for now, as Wall Street grapples…
Shares of Abbott Laboratories rose on Friday after the Club holding company scored a surprise victory in a trial into…
GE Healthcare's quiet outperformance is becoming harder to ignore, and its new drug used in radiology to improve the diagnosis…
AI technology stocks have been all the rage on Wall Street. But here are some events that could boost other…
Jim Cramer's daily rapid-fire breaks down stocks in the news outside of the CNBC Investing Club portfolio. Oracle: The tech…
Eli Lilly's weight-loss drug Zepbound showed promise as a treatment for sleep apnea, giving investors more confidence to continue owning…